Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. Its clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The Company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia and IgA nephropathy.

Type
Public
HQ
South San Francisco, US
Founded
1996
Size (employees)
77 (est)
Website
rigel.com
Rigel Pharmaceuticals was founded in 1996 and is headquartered in South San Francisco, US
Report incorrect company information

Key People/Management at Rigel Pharmaceuticals

Raul R. Rodriguez

Raul R. Rodriguez

President & CEO
Frank Torti

Frank Torti

Investor
Elliott B. Grossbard

Elliott B. Grossbard

Advisor

Rigel Pharmaceuticals Office Locations

Rigel Pharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
1180 Veterans Boulevard
Show all (1)
Report incorrect company information

Rigel Pharmaceuticals Financials and Metrics

Rigel Pharmaceuticals Financials

USD

Net income (FY, 2017)

(78 m)

EBIT (FY, 2017)

(79.6 m)

Market capitalization (20-Apr-2018)

483.1 m

Cash (31-Dec-2017)

38.3 m
Rigel Pharmaceuticals's current market capitalization is $483.1 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

20.9 m37.8 m

R&D expense

63.4 m46.3 m

Operating expense total

84.4 m84.1 m

EBIT

(69.7 m)(79.6 m)
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

5.4 m4.9 m4.1 m4.3 m4.4 m4.8 m4.6 m7.4 m7.8 m

R&D expense

20.1 m16.2 m15.1 m15.5 m18.2 m17.5 m16.2 m12.4 m11.5 m

Operating expense total

25.5 m21 m19.2 m19.8 m22.6 m22.2 m26.5 m19.8 m19.3 m

EBIT

(25.5 m)(21 m)(14 m)(6.8 m)(17.6 m)(13.6 m)(22.7 m)(16.2 m)(19.3 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

20.9 m15.2 m43.5 m17.6 m38.3 m

Accounts Receivable

5.8 m5.8 m203 k

Inventories

Current Assets

220.1 m150.5 m129 m76.2 m117.4 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2017Q2, 2017

Cash

23.9 m12.8 m40.1 m32.6 m

Current Assets

177.5 m158.9 m99.5 m83.8 m

PP&E

3.4 m2.9 m1.1 m982 k

Total Assets

182.4 m163.2 m101.3 m85.5 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(89 m)(90.9 m)(51.5 m)(69.2 m)(78 m)

Depreciation and Amortization

2.6 m2.4 m1.4 m941 k465 k

Inventories

1.9 m722 k

Accounts Payable

2.2 m(2.3 m)1.2 m2.8 m(2.9 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(47.7 m)(68.6 m)(13.9 m)(6.7 m)(17.5 m)(13.5 m)(22.6 m)(15.3 m)(34.5 m)

Depreciation and Amortization

1.3 m1.9 m126 k240 k

Accounts Payable

1 m1.2 m(2 m)(2.9 m)1.1 m1.1 m689 k2.4 m1.5 m1.5 m(4.4 m)(3.5 m)

Cash From Operating Activities

(36.4 m)(54.7 m)(20.8 m)(40.2 m)
USDY, 2017

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Rigel Pharmaceuticals News and Updates

Report incorrect company information